Prognostic Impact of FDG-PET in Surgically Treated Pathological Stage I Lung Adenocarcinoma

被引:7
作者
Higuchi, Mitsunori [1 ]
Hasegawa, Takeo [1 ]
Osugi, Jun [1 ]
Suzuki, Hiroyuki [1 ]
Gotoh, Mitsukazu [1 ]
机构
[1] Fukushima Med Univ, Sch Med, Dept Thorac Surg, Fukushima 9601295, Japan
关键词
18F-deoxyglucose-positron emission tomography; maximum standardized uptake value; pathological stage I lung adenocarcinoma; prognostic factor; lymphovascular involvement; POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; 2ND EDITION; CANCER; SURVIVAL; RECURRENCE;
D O I
10.5761/atcs.oa.12.02219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: This retrospective study evaluated whether the maximum standardized uptake value (SUVmax) on 18F-deoxyglucose (FDG)-positron emission tomography (PET) could be used to predict the prognosis of patients with pathological stage I adenocarcinoma. Methods: We analyzed 138 consecutive patients with pathological stage IA or IB lung adenocarcinoma except pure bronchioloalveolar carcinoma (BAC) who underwent pre-operative FDG-PET imaging and curative resection from January 2005 to October 2010. We analyzed associations between disease-free survival (DFS) and clinicopathological factors. Results: The 5-year DFS rate was 77.7%. Twenty two patients (15.9%) developed recurrence after surgery. Multivariate analysis identified SUVmax and lymphovascular (ly) involvement as the independent prognostic factors for recurrence (p = 0.0255 and p = 0.0333, respectively). We divided the patients into groups according to SUVmax and ly involvement. The 5-year DFS rate was 97.0% in patients with SUVmax <= 2.5 and without ly involvement, 100% with both SUVmax <= 2.5 and ly involvement, 70.2% with SUVmax >2.5 and without ly involvement, and 53.1% with both SUVmax >2.5 and ly involvement. Conclusions: The results of this study suggest that SUVmax and ly involvement could be used to predict the prognosis of patients with pathological stage I adenocarcinoma. The combination of these prognostic factors could also identify high risk groups of recurrence.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 15 条
  • [1] Epidemiology of lung cancer - ACCP evidence-based clinical practice guidelines (2nd edition)
    Alberg, Anthony J.
    Ford, Jean G.
    Samet, Jonathan M.
    [J]. CHEST, 2007, 132 (03) : 29S - 55S
  • [2] Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC) -: A systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project
    Berghmans, Thierry
    Dusart, Michele
    Paesmans, Marianne
    Hossein-Foucher, Claude
    Buvat, Irene
    Castaigne, Catherine
    Scherpereel, Arnaud
    Mascaux, Celine
    Moreau, Michel
    Roelandts, Martine
    Alard, Stphane
    Meert, Anne-Pascale
    Patz, Edward F., Jr.
    Lafitte, Jean-Jacques
    Sculier, Jean-Paul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) : 6 - 12
  • [3] Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection
    Downey, RJ
    Akhurst, T
    Gonen, M
    Vincent, A
    Bains, MS
    Larson, S
    Rusch, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3255 - 3260
  • [4] Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer
    Goodgame, Boone
    Pillot, Giancarlo A.
    Yang, Zhiyun
    Shriki, Jabi
    Meyers, Bryan F.
    Zoole, Jennifer
    Gao, Feng
    Dehdashti, Farrokh
    Patterson, Alexander
    Siegel, Barry A.
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) : 130 - 134
  • [5] HARPOLE DH, 1995, CANCER RES, V55, P51
  • [6] Higashi K, 2000, J NUCL MED, V41, P85
  • [7] FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma
    Kadota, Kyuichi
    Colovos, Christos
    Suzuki, Kei
    Rizk, Nabil P.
    Dunphy, Mark P. S.
    Zabor, Emily C.
    Sima, Camelia S.
    Yoshizawa, Akihiko
    Travis, William D.
    Rusch, Valerie W.
    Adusumilli, Prasad S.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (11) : 3598 - 3605
  • [8] A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Kato, H
    Ichinose, Y
    Ohta, M
    Hata, E
    Tsubota, N
    Tada, H
    Watanabe, Y
    Wada, H
    Tsuboi, M
    Hamajima, N
    Ohta, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) : 1713 - 1721
  • [9] Prognostic value of preoperative FDG-PET in stage IA lung adenocarcinoma
    Murakami, Shuji
    Saito, Haruhiro
    Sakuma, Yuji
    Kondo, Tetsuro
    Oshita, Fumihiro
    Ito, Hiroyuki
    Tsuboi, Masahiro
    Hasegawa, Chikako
    Yokose, Tomoyuki
    Kameda, Youichi
    Nakayama, Haruhiko
    Yamada, Kouzo
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2012, 81 (08) : 1891 - 1895
  • [10] PET Scan 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients With Resected Clinical Stage IA Non-small Cell Lung Cancer
    Nair, Viswani S.
    Barnett, Paul G.
    Ananth, Lakshimi
    Gould, Michael K.
    [J]. CHEST, 2010, 137 (05) : 1150 - 1156